To our knowledge, this is the first report of the production of a highly stable scFv tetramer that inhibits tumor cell growth; therefore, this tetramer is an attractive candidate next‐generation anti‐EGFR therapeutic antibody that can be produced via a low‐cost bacterial expression system. Here, EGFR is linked to neoplasm.